MONTREAL, QC--(Marketwired - May 04, 2016) - Angiochem, a biotechnology company developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain metastases, announced today that the U.S. Food and Drug Administration (FDA) has scheduled an End-of-Phase 2 meeting to discuss clinical study results of the compound. Angiochem submitted a meeting request to the FDA in April 2016; the FDA has scheduled the meeting for June 2016.

"Advancing ANG1005 is Angiochem's top priority," said John Huss, Executive Chairman of Angiochem. "We look forward to discussing our Phase 2 results and plans for a Phase 3 trial at the upcoming meeting with the FDA. ANG1005 is the first of a series of drug-conjugates that could be developed using the Angiopep platform," he added.

The purpose of the End-of-Phase 2 meeting is to determine the adequacy of current studies, and the safety of proceeding to Phase 3. During the meeting, the Phase 3 plan and protocols are evaluated and any additional information necessary to support a marketing application is identified.

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug-conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.